CA2611540C - Sugar chain-containing albumin as a drug carrier to the liver - Google Patents

Sugar chain-containing albumin as a drug carrier to the liver Download PDF

Info

Publication number
CA2611540C
CA2611540C CA2611540A CA2611540A CA2611540C CA 2611540 C CA2611540 C CA 2611540C CA 2611540 A CA2611540 A CA 2611540A CA 2611540 A CA2611540 A CA 2611540A CA 2611540 C CA2611540 C CA 2611540C
Authority
CA
Canada
Prior art keywords
glu
ala
lys
leu
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2611540A
Other languages
French (fr)
Other versions
CA2611540A1 (en
Inventor
Keisuke Nakajou
Naohisa Katayama
Toshiya Kai
Masaki Otagiri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nipro Corp
Original Assignee
Nipro Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nipro Corp filed Critical Nipro Corp
Priority to CA2611540A priority Critical patent/CA2611540C/en
Publication of CA2611540A1 publication Critical patent/CA2611540A1/en
Application granted granted Critical
Publication of CA2611540C publication Critical patent/CA2611540C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A61K38/385—Serum albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Glycosylated albumin as a drug carrier for a DDS targeting the liver (particularly kupffer's cell) can be provided by mutating a DNA encoding albumin to encode a mutant albumin containing a partial amino acid sequence permitting glycosylation modification by eukaryotic cell, preferably a consensus sequence of N-linked sugar chain, introducing an expression vector containing the mutant DNA into a host eukaryotic cell, preferably a host cell permitting addition of a high-mannose type sugar chain, culturing the obtained transformant, and recovering a glycosylated albumin protein from the obtained culture.

Description

SUGAR CHAIN-CONTAINING ALBUMIN AS A DRUG CARRIER TO THE LIVER
THECHNICAL FIELD OF THE INVENTION
The present invention relates to a novel glycosylated albumin protein, wherein a sugar chain is selectively added to a particular amino acid residue, a production method thereof and use thereof. More particularly, the present invention relates to a glycosylated albumin protein wherein a sugar ..zo chain is selectively added to a partial amino acid sequence contained in a mutant albumin, which partial amino acid sequence is possibly subject to a glycosylation modification by a host cell, a DNA encoding the mutant albumin, a production method of the glycosylated albumin protein, comprising cultivating eukaryotic cell containing the DNA, and use of the protein as a drug carrier.
BACKGROUND OF THE INVENTION
Human serum albumin (hereinafter sometimes to be referred to as "HSA") is widely distributed in the body, including blood and intercellular fluids. Its primary structure consists of 585 amino acids, and it is a simple protein having a molecular weight of about 66.5 kDa, which is free of a sugar structure. This protein is produced in the liver, mainly maintains normal osmotic pressure in the bloodstream, and is responsible for maintaining the liquid content of the blood.
Therefore, HSA is used in various clinical situations for the treatment of a condition associated with loss of liquid from the blood vessel, such as surgery, shock, burn, hypoproteinemia causing edema and the like.
In addition, HSA functions as a carrier of various serum molecules, and is rich in safety, biocompatibility, biodegradation property, persistence in blood and the like.
Therefore, it is considered a preferable carrier for a drug delivery system (DDS) of a drUg having a problem in the kinetic property.

The DDS based on an irreversible bond between HSA and a drug includes a method improving persistence in blood of the drug bonded utilizing the long half-life of HSA, and a method using a modified form of HSA as a carrier of the active transport system. In the former, an attempt has been made to express a protein or a bioactive peptide having a short half-life as a hybrid by a gene fusion technique. In the latter, a method of controlling the physicochemical properties of HSA
such as anionization and cationization, and an attempt to /o realize accurate kinetic control and cell-specific targeting by introduction of a recognition element (apparatus) of a receptor, which is present on the cell surface, such as sugar structure and peptide have been intensively studied (Lee YC et al., Biochemisty, 15: 3956-3963, 1976, Opanasopit P et al., Am.
/5 J. Physiol. Gastrointest. Liver Physiol. 280: 879-889, 2001, Takakura Y et al., Int. J. Pharm. 105: 19-29, 1994, Yamasaki Y
et al., J. Pharmacol. Exp. Ther. 301: 467-477, 2002, Nishikawa M et al., Am. J. Physiol. Gastrointest. Liver Physiol.
268:G849-G856, 1995, Higuchi Y et al., Int. J. Pharm. 287:
20 147-154, 2004).
It is known that a receptor that recognizes sugar residue and negative charge is present in the liver. Using this property, albumin bound with succinic acid, galactose, mannose and the like is used for targeting the liver.
25 However, for chemical modification of HSA, the following problems have been pointed out.
(1) The liver does not recognize unless very many sugar residues are bound;
Galactose-modified albumin is not recognized by the liver 30 unless 10 or more galactoses are bound per albumin molecule (see Nishikawa M et al., Am. J. Physiol. Gastrointest. Liver Physiol. 268:G849-G856, 1995).
(2) The cell specificity to liver nonparenchymal cell is low;
Mannose- or fucose-modified albumin is known to be 35 introduced into the both cells of liver endothelial cell and kupffer's cell (see Higuchi Y et al., Int. J. Pharm. 287: 147-154, 2004).
(3) A uniform bound form is difficult to prepare, and appropriate binding conditions need to be found;
and the like. Accordingly, there is a strong demand for the development of a method for modifying HSA by a non-chemical technique.
It is an object of the present invention to provide uniform glycosylated albumin, particularly serum albumin, /o which specifically transfer to the liver, particularly kupffer's cell, thereby providing a drug carrier suitable for DDS to the liver.
The present inventors have conducted intensive studies in an attempt to solve the aforementioned problems and succeeded in preparing a glycosylated HSA with high liver transferability wherein a high-mannose type sugar chain is added to the Asn residue of a consensus sequence (Asn-X-Thr/Ser) by introducing the consensus sequence of an N-linked sugar chain into a DNA encoding HSA by site-directed mutagenesis, and cultivating Pichia pastoris transformed with an expression vector containing the obtained DNA encoding a mutant HSA, which resulted in the completion of the present invention.
SUMMARY OF THE INVENTION
Accordingly, the present invention provides the following.
[1] A glycosylated albumin protein comprising a mutant albumin and a sugar chain, wherein the mutant albumin contains one or more partial amino acid sequences possibly subject to a glycosylation modification by an eukaryotic cell, and the sugar chain is selectively added to the partial amino acid sequence(s).
[2] The protein of the above-mentioned [1], wherein the sugar chain is a high-mannose type sugar chain.
[3] The protein of the above-mentioned [1] or [2], wherein at least one of the partial amino acid sequences is Asn-Xaa-Thr or Asn-Xaa-Ser (Xaa is any genetically encoded amino acid).
[4] The protein of the above-mentioned [3], wherein all the partial amino acid sequences are Asn-Xaa-Thr or Asn-Xaa-Ser (Xaa is any genetically encoded amino acid).
[5] The protein of any of the above-mentioned [1] to [4], wherein the albumin is human serum albumin.
[6] The protein of the above-mentioned [5], which has an amino acid sequence the same as or substantially the same as the amino acid sequence shown in amino acid numbers 1 - 585 in the /o amino acid sequence shown in SEQ ID NO: 2, wherein the 63rd amino acid is Asn and/or the 320th amino acid is Thr or Ser and/or the 494th amino acid is Asn.
[7] The protein of the above-mentioned [6], wherein at least the 494th amino acid is Asn.
[8] A DNA encoding a mutant albumin containing one or more partial amino acid sequences possibly subject to a glycosylation modification by an eukaryotic cell.
[9] An expression vector comprising the DNA of the above-mentioned [8], which is under regulation of a promoter functional in a host eukaryotic cell.
[10] A transformant obtained by introducing the expression vector of the above-mentioned [9] into a host eukaryotic cell.
[11] The transformant of the above-mentioned [10], wherein the host eukaryotic cell is a yeast.
[12] The transformant of the above-mentioned [11], wherein the yeast belongs to the genus Pichia.
[13] A method of producing the protein of the above-mentioned [1], which comprises culturing the transformant of any of the above-mentioned [10] - [12] in a medium, and recovering glycosylated albumin from the obtained culture.
[14] A pharmaceutical agent comprising the protein of any of the above-mentioned [1] - [7].
[15] A drug carrier to the liver, which comprises the protein of any of the above-mentioned [1] - [7].
[16] The carrier of the above-mentioned [15], wherein the target cell is a kupffer's cell.
[17] A pharmaceutical composition comprising a pharmaceutical compound to be delivered to the liver, and the carrier of the above-mentioned [15] or [16].
The present invention as claimed relates to:
- a glycosylated albumin protein comprising a mutant albumin and a sugar chain for use as a drug carrier to the liver, wherein the mutant albumin (i) has an amino acid sequence having not less than 90% identity to the amino acid sequence of wild-type mature human serum albumin (HSA) shown in amino acids 1-585 of SEQ ID NO:4, (ii) contains one or more mutations selected from: (a) substitution of Asp residue shown by amino acid number 63 in the amino acid sequence of SEQ ID
No:4 with Asn residue; (b) substitution of Ala residue shown by amino acid number 320 in the amino acid sequence of SEQ ID No:4 with Thr residue; and (c) substitution of Asp residue shown by amino acid number 494 in the amino acid sequence of SEQ ID No:4 with Asn residue; to constitute partial amino acid sequence(s) that is (are) subject to a glycosylation modification by an eukaryotic cell, and wherein the sugar chain is selectively added to the partial amino acid sequence(s) by the eukaryotic cell containing a DNA encoding the mutant albumin; and - a pharmaceutical composition comprising a pharmaceutical compound to be delivered to the liver, and the glycosylated albumin protein as defined herein, wherein the pharmaceutical compound is an antioxidative substance or nitric oxide.

Since the glycosylated albumin of the present invention is specifically introduced into the liver, particularly liver nonparenchymal cell, more particularly kupffer's cell, it can be used as a drug carrier for the cell.
For example, when the glycosylated albumin of the present invention is bound with an antioxidant or nitric oxide and administered to hepatic ischemia-reperfusion injury, a superior treatment effect can be expected. Moreover, since the liver clearly recognizes even one sugar chain, the albumin can be used without influencing the original structure and function of albumin. In addition, since the albumin is a gene recombinant protein, it is free of a risk of contamination with an unknown virus and the like, which is a problem specific to blood-derived preparations, and can be used safely for human body and the like.
BRIEF DESCRIPTION OF THE DRAWINGS
Fig. I is a graph showing the time course changes of transferability of glycosylated human serum albumin of the present invention to plasma (upper) and liver (lower) in Experimental Example 1, wherein the vertical axis shows a percentage (%) relative to dose and the transverse axis shows time (min) after administration.
Fig. 2 is a graph showing the transfer of "11n-labeled, succinic acid-modified (Suc-)bovine serum albumin (BSA) to plasma (upper), liver (middle) and kidney (lower) when it was intravenously administered to mouse (see Takakura Y et al., Int. J. Pharm. 105: 19-29, 1994), wherein n of Suc,-BSA
shows the number of succinic acid bonded to BSA, = shows 0.1 mg/kg, 0 shows 1 mg/kg, V shows 10 mg/kg and V shows 5a 20 mg/kg each of BSA dose, and the presented data are an excerpt of a related portion from Takakura Y et al., Int. J.
Pharm. 105: 19-29, 1994 added with the vertical axis.
5b DETAILED DESCRIPTION OF THE INVENTION
Examples of the albumin in the present invention include serum albumin, egg white albumin and the like, with preference given to serum albumin. While the origin of albumin is not particularly limited, for example, human and other warm-blooded animals (e.g., bovine, monkey, swine, equine, sheep, goat, canine, feline, rabbit, mouse, rat, hamster, guinea pig, chicken, quail etc.) can be mentioned. In consideration of use as a pharmaceutical agent or a carrier of a pharmaceutical /o compound, preferred is human albumin, more preferred is human serum albumin (NSA). In the following, the present invention is sometimes explained in detail by referring to HSA as an example. Those of ordinary skill in the art can produce and utilize glycosylated albumin in the same manner based on the description in the present specification and other known sequence information of albumin.
The glycosylated albumin of the present invention is a mutant albumin containing one or more partial amino acid sequences possibly subject to a glycosylation modification by an eukaryotic cell, wherein a sugar chain is selectively added to the partial amino acid sequence. Examples of the "partial amino acid sequences possibly subject to a glycosylation modification by an eukaryotic cell" (hereinafter sometimes to be also referred to as "glycosylation sequence") include, but are not limited to, Asn-Xaa-Thr or Asn-Xaa-Ser (Xaa is amino acid genetically coded for and a sugar chain is added to Asn residue) (hereinafter comprehensively abbreviated as "Asn-Xaa-Thr/Ser"), which are consensus sequences of an N-linked sugar chain, Cys-Xaa-Xaa-Gly-Gly-Thr/Ser (Xaa is as defined above, and a sugar chain is added to Thr/Ser residue), which is a consensus sequence of 0-linked fucose from among 0-linked sugar chains, Cys-Xaa-Ser-Xaa-Pro-Cys (Xaa is as defined above, and a sugar chain is added to Ser residue), which is a consensus sequence of 0-linked glucose and the like. Preferred is Asn-Xaa-Thr/Ser, which is a consensus sequence of N-linked sugar chain. The number of the glycosylation sequences may be one or more. While the liver, particularly kupffer's cell, targeting efficiency is improved as the number of sugar chains increases, in consideration of the maintenance of the original physiological function of albumin and the antigenicity problem, a smaller number of sugar chains to be added is more advantageous. As mentioned below, the liver targeting function does not simply depend on the number of sugar chains to be added, but varies depending on the site of addition. Thus, /o introduction of a glycosylation sequence into a site highly contributing to the targeting efficiency achieves superior targeting efficiency with a small number of sugar chains.
Since natural (wild-type) albumin is a simple protein, it does not have a partial amino acid sequence that may undergo a /5 glycosylation modification by an eukaryotic cell. Accordingly, the glycosylated albumin of the present invention comprises a mutant amino acid sequence containing the above-mentioned glycosylation sequence. While the mutant albumin polypeptide of the present invention may be obtained by any method, for a 20 sugar chain to be selectively added to the glycosylation sequence in the polypeptide, the mutant albumin polypeptide is preferably provided by cultivating an eukaryotic cell containing a DNA encoding the same.
While the eukaryotic cell containing a DNA encoding the 25 mutant albumin can also be obtained, for example, by inducing a mutation inartificially or artificially (e.g., treatment with mutagenic agent such as EMS and the like, UV treatment and the like) in a cell (e.g., hepatocyte and the like) inherently producing albumin and screening for a cell 30 producing a mutant albumin containing a glycosylation sequence, it can be more preferably produced by cloning a DNA encoding albumin, introducing a base sequence encoding a glycosylation sequence into the DNA by a genetic manipulation, inserting the obtained mutant DNA into an expression vector containing a 35 promoter functional in a suitable host eukaryotic cell so that it will enter the control of the promoter, and transforming the host eukaryotic cell with the obtained mutant albumin expression vector.
Examples of the DNA encoding albumin include genomic DNAs derived from human or other warm-blooded animals, cDNAs derived from albumin-producing cells (e.g., hepatocyte and the like), synthetic DNA and the like. The genomic DNA or cDNA
encoding albumin can also be directly amplified by Polymerase Chain Reaction (hereinafter abbreviated as "PCR method") or lo Reverse Transcriptase-PCR (hereinafter abbreviated as "RT-PCR
method") using a genomic DNA fraction or a total RNA or mRNA
fraction prepared from the producing cells or tissues (e.g., liver and the like) as a template. Alternatively, the genomic DNA or cDNA encoding albumin can also be cloned by colony or plaque hybridization method, PCR method and the like from a genomic DNA library or cDNA library prepared by inserting a fragment of genomic DNA or total RNA or mRNA prepared from the above-mentioned cell/tissue into a suitable vector. The vector to be used for the library may be any of bacteriophage, plasmid, cosmid, phagemid and the like.
Examples of the DNA encoding albumin include a DNA
containing a base sequence encoding an amino acid sequence the same as or substantially the same as the amino acid sequence shown in amino acid numbers 1 - 585 in the amino acid sequence shown in SEQ ID NO: 4 (wild-type mature HSA) and the like. As the amino acid sequence substantially the same as the amino acid sequence shown in amino acid numbers 1 - 585 in the amino acid sequence shown in SEQ ID NO: 4, an amino acid sequence having a homology of not less than about 80%, preferably not less than about 90%, more preferably not less than about 95%, particularly preferably not less than about 98% with the amino acid sequence shown in the amino acid sequence shown in amino acid numbers 1 - 585 in the amino acid sequence shown in SEQ
ID NO: 4 and the like can be mentioned. As used herein, by the "homology" is meant the proportion (%) of the same amino acid and similar amino acid residues relative to the total overlapping amino acid residues in the optimal alignment when two amino acid sequences are aligned using a mathematical algorithm known in the art (preferably, the algorithm is capable of considering introduction of a gap into one or both of the sequences for the optimal alignment). The "similar amino acid" means an amino acid similar in the physicochemical properties. For example, amino acids classified in the same group such as aromatic amino acids (Phe, Trp, Tyr), aliphatic /o amino acids (Ala, Leu, Ile, Val), polar amino acids (Gin, Asn), basic amino acids (Lys, Arg, His), acidic amino acids (Glu, Asp), amino acids (Ser, Thr) having a hydroxyl group, amino acids (Gly, Ala, Ser, Thr, Met) with small side chain and the like can be mentioned. It is predicted that substitution with /5 such similar amino acids will not alter protein phenotypes (namely, preservative amino acid substitution). Specific examples of preservative amino acid substitution are well known in the art and are described in various literatures (see e.g., Bowie et al., Science, 247: 1306-1310 (1990)).
20 The homology of the amino acid sequence in the present . specification can be calculated using homology calculation algorithm NCBI BLAST (National Center for Biotechnology Information Basic Local Alignment Search Tool) under the following conditions (expectancy=10; allowing gap;
25 matrix=BLOSUM62; filtering=OFF). Other algorithms for determining the homology of the amino acid sequence include, for example, the algorithm described in Karlin et al., Proc.
Natl. Acad. Sci. USA, 90: 5873-5877 (1993) [this algorithm is incorporated in the NBLAST and XBLAST program (version 2.0) 30 (Altschul et al., Nucleic Acids Res., 25: 3389-3402 (1997))], the algorithm described in Needleman et al., J. Mol. Biol., 48: 444-453 (1970) [this algorithm is incorporated in the GAP
program in the GCG software package], the algorithm described in Myers and Miller, CABIOS, 4: 11-17 (1988) [this algorithm 35 is incorporated in the ALIGN program (version 2.0) which is a part of the CGC sequence alignment software package], the algorithm described in Pearson et al., Proc. Natl. Acad. Sci.
USA, 85: 2444-2448 (1988) [this algorithm is incorporated in the FASTA program in the GCG software package] and the like, and they can also be used preferably.
More preferably, an amino acid sequence substantially the same as the amino acid sequence shown in amino acid numbers 1 - 585 in the amino acid sequence shown in SEQ ID NO: 4 has homology of not less than about 80%, preferably not less than /0 about 90%, more preferably not less than about 95%, particularly preferably not less than about 98%, to the amino acid sequence shown in amino acid numbers 1 - 585 in the amino acid sequence shown in SEQ ID NO: 4.
A protein containing an amino acid sequence substantially the same as the amino acid sequence shown in amino acid numbers 1 - 585 in the amino acid sequence shown in SEQ ID NO:
4 means a protein containing an amino acid sequence substantially the same as the aforementioned amino acid sequence shown in amino acid numbers 1 - 585 in the amino acid sequence shown in SEQ ID NO: 4 and having a substantially equivalent activity to that of the protein containing the amino acid sequence shown in amino acid numbers 1 - 585 in the amino acid sequence shown in SEQ ID NO: 4.
The substantially the equivalent activity includes, for example, physiological function of albumin (particularly serum albumin), such as function as a carrier of serum molecules, function to maintain plasma colloidal osmotic pressure and the like. The "substantially equivalent" means that the functions are qualitatively the same. Therefore, the function as a carrier of the serum molecules and the like is preferably equivalent, but the quantitative elements such as the level of the function, molecular weight of the protein and the like may be different.
In addition, the DNA encoding albumin includes, for example, DNA encoding a protein containing (1) an amino acid sequence wherein one or more (preferably about 1 - 30, more preferably about 1 - 10, particularly preferably 1 - several (2, 3, 4 or 5)) amino acids are deleted from the amino acid sequence shown in amino acid numbers 1 - 585 of the amino acid sequence shown in SEQ ID NO: 4, (2) an amino acid sequence wherein one or more (preferably about 1 - 30, more preferably about 1 - 10, particularly preferably 1 - several (2, 3, 4 or 5)) amino acids are added to the amino acid sequence shown in amino acid numbers 1 - 585 in the amino acid sequence shown in lo SEQ ID NO: 4, (3) an amino acid sequence wherein one or more (preferably about 1 - 30, more preferably about 1 - 10, particularly preferably 1 - several (2, 3, 4 or 5)) amino acids are inserted in the amino acid sequence shown in amino acid numbers 1 - 585 in the amino acid sequence shown in SEQ
ID NO: 4, (4) an amino acid sequence wherein one or more (preferably about 1 - 30, more preferably about 1 - 10, particularly preferably 1 - several (2, 3, 4 or 5)) amino acids are substituted by other amino acids in the amino acid sequence shown in amino acid numbers 1 - 585 in the amino acid sequence shown in SEQ ID NO: 4, or (5) a combination of these, and the like.
When the amino acid sequence is inserted, deleted or substituted as mentioned above, the site of the insertion, deletion or substitution is not particularly limited as long as the activity of protein is maintained.
More preferably, a DNA encoding albumin (particularly HSA) includes, for example, a DNA containing the base sequence shown in base numbers 73 - 1827 in the base sequence shown in SEQ ID NO: 3, a DNA encoding a protein having a base sequence hybridizing to the base sequence shown in SEQ ID NO: 3 under stringent conditions, and having substantially equivalent activity (e.g., function of serum molecule as a carrier and the like) to a protein containing the aforementioned amino acid sequence shown in amino acid numbers 1 - 585 of the amino acid sequence shown in SEQ ID NO: 4, and the like. As the DNA

capable of hybridizing to the base sequence shown in SEQ ID
NO: 3 under stringent conditions, for example, a DNA
containing a base sequence having, in an overlapping region, a homology of not less than about 80%, preferably not less than about 90%, more preferably not less than about 95%, to the base sequence shown in base numbers 73 - 1827 in the base sequence shown in SEQ ID NO: 3 and the like can be used.
The homology of the base sequence in the present specification can be calculated using a homology calculation /o algorithm NCBI BLAST (National Center for Biotechnology Information Basic Local Alignment Search Tool) under the following conditions (expectancy=10; allowing gap;
filtering=0N; match score=1; mismatch score=-3). Preferable examples of other algorithms usable for determining homology of the base sequence include the above-mentioned homology calculation algorithms for amino acid sequence.
Hybridization can be performed according to a method known per se or a method according to the method, for example, the method described in Molecular Cloning, ver. 2 (J. Sambrook et al., Cold Spring Harbor Lab. Press, 1989) and the like.
When a commercially available library is used, moreover, hybridization can be performed according to the method described in the attached instruction manual. Preferably, hybridization can be performed under high stringent conditions.
The high stringent conditions include, for example, a hybridization reaction at 45 C in 6xSSC (sodium chloride/sodium citrate), and washing one or more times at 65 C in 0.2xSSC/0.1%
SDS and the like. Those of ordinary skill in the art can easily adjust to the desired stringency by appropriately changing the salt concentration of hybridization solution, temperature of hybridization reaction, probe concentration, length of probe, number of mismatches, hybridization reaction time, salt concentration of washing solution, temperature of washing and the like.
A DNA encoding albumin (particularly HSA) can be cloned by amplifying by PCR method using a synthetic DNA primer having a part of the base sequence encoding albumin, or hybridizing DNA incorporated into a suitable expression vector to with a labeled DNA fragment or synthetic DNA encoding a part or full region of albumin.
As a method for introducing a base sequence encoding a glycosylation sequence into a DNA encoding albumin (particularly HSA) obtained as mentioned above, site-directed mutagenesis known per se (e.g., Examples below) and the like lo can be used. A glycosylation sequence-coding sequence may be introduced into any part of the DNA encoding albumin. In the case of site-directed mutagenesis using PCR method, wherein, for example, a base sequence encoding consensus sequence Asn-Xaa-Thr/Ser of N-linked sugar chain is introduced, the sequence is preferably introduced into a site encoding the Asn residue of a DNA encoding albumin or a site encoding the Thr or Ser residue thereof. To be specific, a base sequence encoding a consensus sequence of N-linked sugar chain can be introduced by PCR using a DNA encoding albumin as a template, and (1) an oligonucleotide complementary to a region containing a base sequence encoding any Asn-Xaal-Xaa2 site in the albumin (provided the codon corresponding to Xaa2 is substituted by a codon encoding Thr or Ser) or (2) an oligonucleotide complementary to a region containing a base sequence encoding any Xaal-Xaa2-Thr/Ser site in the albumin (provided the codon corresponding to Xaal is substituted by a codon encoding Asn) as one primer. The glycosylation sequence can be made to be present in the DNA not only by amino acid substitution as mentioned above, but also by inserting a base sequence encoding an amino acid (or amino acid sequence) into a DNA encoding albumin or deleting a base sequence encoding an amino acid (or amino acid sequence) from the DNA by a similar method.
In the case of HSA, for example, more preferably, a consensus sequence of N-linked sugar chain can be introduced by substituting Asp residue shown by amino acid number 494 in the amino acid sequence shown in SEQ ID NO: 4 with Asn residue (Asn494) (see SEQ ID NO: 2). Glycosylated HSA wherein a sugar chain is added to Asn494 can be targeted to the liver at an efficiency equal to more than that of glycosylated albumin (having a number of sugar chains) obtained by conventionally known chemical modification, even though the number of sugar chain in the molecule is only one. In another preferable embodiment, a consensus sequence of N-linked sugar chain can /o be introduced by substituting Asp residue shown by amino acid number 63 in the amino acid sequence shown in SEQ ID NO: 4 with Asn residue (Asn63), or by substituting Ala residue shown by amino acid number 320 with Thr or Ser residue (Thr/Ser320) (see SEQ ID NO: 2). In a particularly preferable embodiment, glycosylated HSA of the present invention can further contain, in addition to Asn434, one or more glycosylation sequences, preferably consensus sequence Asn-Xaa-Thr/Ser of N-linked sugar chain. As a further sugar chain addition site, the above-mentioned Asn63 and/or Asn318 resulting from the above-mentioned substitution with Thr/Ser32 can be mentioned.
An expression vector containing a DNA encoding a mutant albumin containing one or more partial amino acid sequences possibly subject to a glycosylation modification by an eukaryotic cell, which has been cloned as mentioned above, can be produced by ligating the DNA to a downstream of a promoter in a suitable expression vector using a restriction enzyme and a DNA ligase.
As the expression vector, bacteriophage such as plasmid derived from Escherichia coli (e.g., pBR322, pBR325, pUC12, pUC13), plasmid derived from Bacillus subtilis (e.g., pUB110, pTP5, pC194), plasmid derived from yeast (e.g., pSH19, pSH15), X-phage and the like, animal (insect) virus such as retrovirus, vaccinia virus, baculovirus and the like, pA1-11, pXT1, pRc/CMV, pRc/RSV, pcDNAI/Neo and the like are used.
The promoter may be any as long as it is an appropriate promoter corresponding to the host used for gene expression.
In the present invention, any can be used as a host cell without any particular limitation as long as it has a glycosylation modification mechanism to add a sugar chain to the glycosylation sequence contained in the mutant albumin of the present invention and, for example, various eukaryotic cells such as animal cell including mammal, insect cell, plant cell, yeast cell, fungal cell and the like, or transgenic animal/plant or insect and the like can be used.
io For example, when the host is a yeast, a PHO5 promoter, a PGK promoter, a GAP promoter, an ADH promoter and the like are preferable.
When the host is an animal cell, a promoter derived from cytomegalovirus (CMV) (e.g., CMV immediate-early promoter), a promoter derived from human immunodeficiency virus (HIV) (e.g., HIV LTR), a promoter derived from Rous sarcoma virus (RSV) (e.g., RSV LTR), a promoter derived from mouse mammary tumor virus (MMTV) (e.g., MMTV LTR), a promoter derived from Moloney murine leukemia virus (MoMLV) (e.g., MMTV LTR), a promoter derived from simple herpes virus (HSV) (e.g., HSV thymidine kinase (TI() promoter), a promoter derived from SV40 promoter (e.g., SV40 early promoter), a promoter derived from Epstein-Barr virus (EBV), a promoter derived from adeno-associated virus (AAV) (e.g., AAV p5 promoter), a promoter derived from adenovirus (AdV) (Ad2 or Ad5 major late promoter) and the like can be used.
When the host is an insect cell, a polyhedrin promoter, a P10 promoter and the like are preferable.
As the expression vector, besides those mentioned above, one containing an enhancer, a splicing signal, a polyA
addition signal, a selection marker, an SV40 replication origin and the like on demand can be used. As the selection marker, for example, dihydrofolate reductase (dhfr) gene [methotrexate (MTX) resistance], ampicillin resistance (Ampr) gene, neomycin resistance (Neor) gene (G418 resistance) and the like can be mentioned. Particularly, when dhfr-deficient Chinese hamster (CHO-dhfri cell is used and dhfr gene is used as a selection marker, the object gene can also be selected in a thymidine-free medium. Moreover, when the DNA to be inserted does not contain an initiation codon and a stop codon, a vector containing an initiation codon (ATG or GTG) and a stop codon (TAG, TGA, TAA) at the downstream of promoter region and at the upstream of terminator region, respectively, is preferably used.
Where necessary, a base sequence encoding a signal sequence suitable for the host (signal codon) may be added to the 5' end side of a DNA encoding the mutant albumin. For example, when the host is a yeast, MFa signal sequence, SUC2 signal sequence and the like can be used. When the host is an animal cell, insulin signal sequence, a-interferon signal sequence, antibody molecule signal sequence and the like can be used. However, since native prepro-sequence of HSA (amino acid sequence shown by amino acid number -24 to -1 in the amino acid sequence shown in SEQ ID NO: 4) is known to function as a secretion signal in most heterologous eukaryotic cells, a DNA encoding prepro-HSA can also be directly inserted into an expression vector.
As mentioned above, for example, yeast, insect cell, insect, animal cell, animal and the like are used as a host.
As the yeast, for example, Saccharomyces cerevisiae AH22, AH22R-, NA87-11A, DKD-5D, 20B-12, Schizosaccharomyces pombe NCYC1913, NCYC2036 and the like are used.
As the insect cell, for example, when the virus is AcNPV, established cell line derived from Spodoptera frugiperda larva (Spodoptera frugiperda cell; Sf cell), MG1 cell derived from Trichoplusia ni midgud, High Fiveml cell derived from Trichoplusia ni egg, cell derived from Mamestra brassicae, cell derived from Estigmena acrea and the like are used. When the virus is BmNPV, established cell line derived from silkworm (Bombyx mori N cell; BmN cell) and the like are used as the insect cell. As the Sf cell, for example, Sf9 cell (ATCC CRL1711), Sf21 cell (both in Vaughn, J.L. et al., In Vivo, 13, 213-217 (1977)) and the like are used.
As the insect, for example, Bombyx mori larva and the like are used.
As the animal cell, for example, cell derived from monkey (e.g., COS-1, COS-7, CV-1, Vero), cell derived from hamster (e.g., BHK, CHO, CHO-K1, CHO-dhfr), cell derived from mouse (e.g., NIH3T3, L, L929, CTLL-2, AtT-20), cell derived from rat /o (e.g., H4IIE, PC-12, 3Y1, NBT-II), cell derived from human (e.g., HEK293, A549, HeLa, HepG2, HL-60, Jurkat, U937) and the like are used.
Transformation can be performed according to a known method depending on the kind of the host.
For example, yeast can be transformed according to the methods described in Methods in Enzymology, 194, 182-187 (1991), Proc. Natl. Acad. Sci. USA, 75, 1929 (1978) and the like.
For example, insect cell and insect can be transformed according to the methods described in Bio/Technology, 6, 47-55 (1988) and the like.
For example, animal cell can be transformed according to the methods described in Saibo Kogaku, extra issue 8, Shin Saibo Kogaku Jikken Protocol, 263-267 (1995)(published by Shujunsha) and Virology, 52, 456 (1973).
The transformant can be cultured according to a known method depending on the kind of the host.
As the medium, a liquid medium is preferable. The medium preferably contains a carbon source, a nitrogen source, an inorganic substance and the like necessary for the growth of the transformant. Here, as the carbon source, for example, glucose, dextrin, soluble starch, sucrose and the like can be used; as the nitrogen source, for example, inorganic or organic substances such as ammonium salts, nitrate salts, corn steep liquor, peptone, casein, meat extract, soybean cake, potato extract and the like can be used; and as the inorganic substance, for example, calcium chloride, sodium dihydrogen phosphate, magnesium chloride and the like can be used. The medium may contain a yeast extract, vitamins, a growth-promoting factor and the like. The pH of the medium is preferably about 5 - 8.
As a medium for cultivating a transformant whose host is a yeast, for example, Burkholder minimum medium, SD medium containing 0.5% casamino acid and the like can be mentioned.
The pH of the medium is preferably about 5 - 8. The culture is generally performed at about 20 C - 35 C for about 24 - 72 hr.
Where necessary, aeration and agitation may also be performed.
As a medium for cultivating a transformant whose host is an insect cell or a insect, for example, Grace's Insect Medium is appropriately supplemented with an additive such as inactivated 10% bovine serum and the like, and the like are used. The pH of the medium is preferably about 6.2 - 6.4. The culture is generally performed at about 27 C for about 3 - 5 days. Where necessary, aeration and agitation may also be performed.
As a medium for cultivating a transformant whose host is an animal cell, for example, minimum essential medium (MEM), Dulbecco's Modified Eagle Medium (DMEM), RPMI1640 medium, 199 medium and the like supplemented with about 5 - 20% of fetal bovine serum are used. The pH of the medium is preferably about 6 - 8. The culture is generally performed at about 30 C
- 40 C for about 15 - 60 hr. Where necessary, aeration and agitation may also be performed.
In this manner, Glycosylated albumin can be intracellularly or extracellularly provided by a transformant.
Since the glycosylated albumin of the present invention can be preferably used as a carrier molecule capable of specific transfer to the liver, particularly kupffer's cell, one wherein a high-mannose type sugar chain having high affinity for a receptor on the cell surface is added is more
18 preferable. Here, the "high-mannose type" means a sugar chain wherein one or more, preferably two or more, more preferably three or more, particularly preferably five or more, mannose molecules are further added to the core sugar chain (including three mannose molecules). From such aspects, a yeast cell, permitting addition of only a hyper-mannose type sugar chain and also permitting addition of a hyper-mannose type sugar chain having still more mannose molecules than those in animal cell and the like, is more preferable as a host cell, than /o animal cell and insect cell capable of a different glycosylation modification such as those of a complex type and a mixed type in addition to a high-mannose type. Particularly, a yeast of the genus Pichia can grow utilizing methanol as a sole carbon source, and when grown in methanol, an enzyme necessary for treating methanol and a metabolic intermediate thereof are disinhibited and expressed. It. is known that the secretion expression level of a heterologous protein markedly exceeds that of Saccharomyces yeast when the methanol-utilizing pathway is used. In fact, production of HSA using this system is in the phase of practical application (e.g., JP-A-6-22784), where HSA of a 10 g order can be produced from 1 L of a medium. In the following, as one of the particularly preferable embodiments of the present invention, a production method of the glycosylated albumin of the present invention, which uses a Pichia yeast as a host cell, is explained.
The vector to be used is not particularly limited as long as it can be maintained genetically stably by autonomous replication in a fungus body of yeast of the genus Pichia or integration into a yeast genome. Examples of the autonomously-replicable vector include YEp vector, YRp vector, YCp vector and the like. In addition, examples of the vector to be integrated into a yeast genome include YIp vector and YRp vector.
Examples of the promoter functional in the yeast of the genus Pichia include promoters derived from a yeast, such as
19 PHO5 promoter, PGK promoter, GAP promoter, ADH promoter derived from S. cerevisiae and the like, alcohol oxidase (AOX) 1 promoter, A0X2 promoter, dihydroxyacetone synthase promoter, P40 promoter, ADH promoter, folic acid dehydrogenase promoter derived from P. pastoris and the like. In addition, the above-mentioned promoter derived from a yeast may be a mutant promoter modified to further improve the gene expression efficiency, for example, mutant A0X2 (mA0X2) promoter [Ohi et al., Mol. Gen. Genet., 243, 489-499 (1994); JP-A-4-299984] and /o the like. Preferably, the promoter is a promoter of an enzyme gene necessary for treating methanol or a metabolic intermediate thereof, in order to use a methanol-metabolizing system in the yeast of the genus Pichia, such as A0X1 promoter, mA0X2 promoter and the like.
The expression vector containing the DNA encoding mutant albumin of the present invention preferably further contains transcription terminator sequence (terminator) functional in a yeast of the genus Pichia (e.g., A0X1 terminator etc.), enhancer sequence, selection marker gene usable for selecting yeast (auxotrophic gene, for example, HIS4, LEU2, ARG4 and URA3 gene derived from P. pastoris or S. cerevisiae, and the like, or antibiotic resistance gene, for example, resistance gene to cycloheximide, G-418, chloramphenicol, bleomycin, hygromycin etc., and the like) and the like, and when desired, may contain replicable unit functional in yeast. For preparation of the vector in a large amount, moreover, the vector more preferably contains a replicable unit functional in Escherichia coli and a selection marker gene usable for selecting Escherichia coli (e.g., resistance gene to ampicillin and tetracycline etc.) When the expression vector is of a type incorporated into a yeast genome, the vector preferably further contains a sequence homologous to a yeast genome necessary for homologous recombination. As such homology sequence, the aforementioned auxotrophic gene sequence can be mentioned. Accordingly, in one preferable embodiment, the expression vector of the present invention is one wherein an expression cassette of the above-mentioned mutant albumin is inserted in an auxotrophic gene (in the present specification, the "expression cassette"
means a unit enabling gene expression, whose minimal unit is a protein-coding sequence configured under regulation of a promoter, with preference given to a unit comprising promoter-protein-coding region-terminator).
The expression vector obtained as mentioned above can be /0 introduced into the fungus body of the target yeast of the genus Pichia using, for example, a known transformation technique such as competent cell method, protoplast method, calcium phosphate coprecipitation method, polyethylene glycol method, lithium method, electroporation method, microinjection method, liposome fusion method, particle gun method and the like.
While the yeast of the genus Pichia to be used in the present invention is not particularly limited, for example, P.
pastoris, Pichia acaciae, Pichia angusta, Pichia anomala, Pichia capsulata, Pichia ciferrii, Pichia etchellsii, Pichia fabianii, Pichia farinosa, Pichia guilliermondii, Pichia inositovora, Pichia jadinii, Pichia methanolica, Pichia norvegensis, Pichia ofunaensis, Pichia pinus and the like can be used. Preferred is P. pastoris, particularly, auxotrophic mutant P. pastoris strain (e.g., P. pastoris GTS115 strain (HIS4) [NNRL Y-15851], P. pastoris GS190 strain (ARG41 [NNRLY-1801], P. pastoris PPF1 (HIS4-= URA4-) [NNRL Y-18017] and the like).
By cultivating the transformed yeast of the genus Pichia by a method generally used in the art, glycosylated albumin can be produced. The medium to be used needs to contain at least a carbon source and an inorganic or organic nitrogen source necessary for the growth of the host cell. Examples of the carbon source include methanol, glycerol, glucose, sucrose, dextran, soluble starch and the like. In addition, examples of the inorganic or organic nitrogen source include ammonium salts, nitrate salts, amino acid, corn steep liquor, peptone, casein, meat extract, yeast extract, soybean cake, potato extract and the like. When desired, moreover, other nutrients, for example, inorganic salts such as calcium chloride, sodium dihydrogenphosphate, magnesium chloride and the like, vitamins such as biotin and the like, antibiotic and the like can be added.
Examples of the medium to be used include conventional lo natural medium (e.g., YPD medium, YPM medium, YPG medium etc.) and synthetic medium. As the pH and culture temperature of the medium, those suitable for the growth of yeast and production of albumin are employed. For example, pH of about 5 - about 8 and culture temperature of about 20 C - about 30 C are preferable. In addition, aeration and agitation are performed as necessary. The culture is generally performed for about 48 - about 120 hr.
For example, when a promoter whose expression is induced by methanol, such as A0X1 promoter, mA0X2 promoter and the like, is used as a promoter functional in the fungus body of a yeast of the genus Pichia, a method of liquid aeration-agitation culture using natural medium controlled to pH about 6.0, which contains glycerol as a carbon source for the growth of fungus body and methanol as albumin expression inducer is most preferable. When the expression of albumin is not preferable for the growth of fungus body, a method including first increasing the amount of fungus body with a carbon source other than methanol, and inducing the expression of albumin by addition of methanol is more preferable. In a culture in a jarfermenter, moreover, a high density culture method is suitable for the production of albumin. The culture may be performed by any of batch culture, feeding culture and continuous culture, with preference given to feeding culture method. That is, for a certain period, a method including culturing the host fungus body in a medium (initial medium) containing a carbon energy source suitable for the growth (e.g., glucose etc.) and/or a nutrient source, and confining albumin in the system until completion of the culture while additionally supplying a substrate controlling the growth of the host cell (that is, methanol) to the medium from a certain point in time according to the situation can be used (see e.g., JP-A-3-83595).
Albumin produced in the culture can be isolated and purified by centrifugation and/or filtration of the culture /o after completion of the culture to give a culture supernatant (in the case of secretory expression) or fungus body of yeast (in the case of expression in fungus body), which is then treated according to a method known per se. As such method, a method utilizing the solubility such as salting out, solvent precipitation and the like; a method mainly utilizing difference in the molecular weight such as dialysis, ultrafiltration, gel filtration method, SDS-polyacrylamide gel electrophoresis and the like; a method utilizing difference in the electric charge such as ion exchange chromatography and the like; a method utilizing specific affinity such as affinity chromatography and the like; a method utilizing difference in hydrophobicity such as reversed-phase high performance liquid chromatography and the like; a method utilizing difference in the isoelectric point such as isoelectric focusing and the like; and the like can be used.
These methods can be appropriately combined.
Examples of a method for confirming the isolated and purified glycosylated albumin include known Western blotting method and the like. In addition, the structure of the purified glycosylated albumin can be clarified by amino acid analysis, N-terminal amino acid sequence, primary structure analysis, sugar chain analysis and the like.
The thus-obtained glycosylated albumin is a uniform glycoprotein wherein a sugar chain, preferably a high-mannose type sugar chain, is selectively added to the glycosylation sequence of a mutant albumin, and therefore shows high transferability to the nonparenchymal cells of the liver, particularly kupffer's cell. Accordingly, the present invention also provides a drug carrier to the liver, which contains the above-mentioned glycosylated albumin of the present invention.
Since the drug carrier of the present invention, which contains the glycosylated albumin of the present invention (particularly HSA) as a main component, can be utilized for /o targeting any pharmaceutical compound that becomes effective for the prophylaxis and/or treatment on delivery to the liver, preferably hepatic nonparenchymal cells, particularly kupffer's cell, to the organ or cell. Examples of such pharmaceutical compound include antioxidative substances (e.g., N-acetylcysteine, ascorbic acid etc.), nitric oxide and the like. A preparation wherein the pharmaceutical compound is bound with the glycosylated albumin of the present invention can be used for the treatment of hepatic ischemia-reperfusion injury. Moreover, examples of other pharmaceutical compounds include a hepatic drug such as hepatic fibrosis treatment drug 0K432, and the like. Since albumin itself also has an antioxidative action, it can be directly used as a pharmaceutical product having an antioxidative action.
The binding mode of glycosylated albumin and a pharmaceutical compound is not particularly limited. For example, covalent bond, hydrogen bond, hydrophobic bond and the like can be used, with preference given to a covalent bond.
The method for binding albumin with a pharmaceutical compound is known and, for example, "Drug Delivery System" (1986, published by CMC) can be referred to.
A pharmaceutical compound-glycosylated albumin conjugate can be processed into a preparation by a known method (ultrafiltration, sterilizing by filtration, dispension, freeze-drying etc.) Specifically, a liquid preparation containing 5 - 25% of the conjugate and having a pH of about 6.4 - 7.4 and an osmotic pressure ratio of about 1 can be mentioned. Where necessary, the preparation can contain acetyltryptophan or a salt thereof (e.g., sodium salt) and sodium caprylate as stabilizers. The amount of the stabilizer to be added is, for example, about 0.01 - 0.2M, preferably about 0.02 - 0.05M. In addition, the sodium content is, for example, not more than 3.7 mg/ml. The timing of addition of the stabilizer is before treatment by ultrafiltration, sterilizing by filtration, dispension, freeze-drying and the _to like.
The medical preparation of the present invention obtained via the above-mentioned steps is considered to have an extremely slim possibility of contamination with various microorganisms. As a method for more positively securing the is aseptic nature of the preparation, inactivation of contaminating microorganisms can be performed by applying a heat treatment (pasteurization) after aseptic filling.
By a heat treatment including keeping a preparation filled in a container per unit dose, irrespective of the kind
20 of the container to be filled in, for example, for not less than about 30 min in a hot water bath at about 50 C - about 70 C (preferably about 60 C), contaminating microorganisms can be inactivated sufficiently. The heating time is preferably about 30 min - about 2 hr.
25 The pharmaceutical preparation can be administered, for example, as an injection to human, other mammals and the like.
While the dose of the preparation varies depending on the kind of pharmaceutical compound, administration route, severity of disease, animal species to be the subject of administration, 30 and drug acceptability, body weight, age and the like of the administration subject, it is, for example, in the case of a hepatic ischemia-reperfusion injury therapeutic agent containing nitric oxide as an active ingredient, generally 0.1 - 30 g/kg/day, preferably 0.5 - 3 g/kg/day, in a nitric oxide 35 amount for an adult, and about 0.1 - 30 mg/kg/day, preferably 0.5 - 3 mg/kg/day, in a glycosylated albumin amount for an adult. This amount is contained in a solution (about 5 - about ml), and slowly administered by an intravenous injection or drip intravenous administration.
Albumin (particularly HSA) per se can be used as a pharmaceutical agent, for example, mainly for the purpose of rapidly extending plasma during shock, supplementing the amount of circulating blood, improving hypoproteinemia, sustaining colloid osmotic pressure and the like. As specific lo efficacy-effect, it is effective for hypoalbuminemia due to loss of albumin (burn, nephrosis syndrome etc.) and suppression of albumin synthesis (hepatic cirrhosis etc.), hemorrhagic shock and the like. Accordingly, the glycosylated albumin of the present invention can also be used as a pharmaceutical agent for improving such disease and condition.
Also in this case, albumin can be processed into an injectable preparation in the same manner as above.
While the dose of albumin preparation varies depending on the administration route, severity of disease, animal species to be the subject of administration, and drug acceptability, body weight, age and the like of the administration subject, it is generally 20 - 25 ml of HSA 25% solution (5 - 12.5 g as HSA) for a single dose to an adult, which is gradually given by intravenous injection or intravenous drip infusion.
While the present invention is explained in detail in the following by referring to Examples, the present invention is not limited by these.
EXAMPLES
Example production of glycosylated albumin (1) mutation of albumin gene Using plasmid pPIC9 into which human serum albumin gene was introduced (hereinafter pPIC9-HSA) as a template, and D63N
sense primer of SEQ ID NO: 5 (5'-GAGTCAGCTGAAAATTGTAACAAATCACTTCATACCC-3') and D63N antisense primer of SEQ ID NO: 6 (5'-GGGTATGAAGTGATTTGTTACA1TTTTCAGCTGACTC-3') for preparation of Asn63-linked glycosylated albumin, A320T sense primer of SEQ ID
NO: 7 (5'-GGATGTTTGCAAAAACTATACTGAGGCAAAGG-3') and A320T
antisense primer of SEQ ID NO: 8 (5'-CCTTTGCCTCAGTATAGTTTTTGCAAACATCC-3') for preparation of Asn318-linked glycosylated albumin, and D494N sense primer of SEQ ID
NO: 9 (5'-GCTCTGGAAGTCAATGAAACATACGTTCCC-3') and D494N
antisense primer of SEQ ID NO: 10 (5'-GGGAACGTATGTTTCATTGACTTCCAGAGC-3') for preparation of Asn494-/0 linked glycosylated albumin as synthetic primers, mutations of N-linked sugar chain consensus sequences were performed (QuikChange XL Site-Directed Mutagenesis Kit, Stratagene). As for mutation reaction conditions, DNA was treated for 30 sec at 95 C, after which a 12-cycle reaction of denaturation (95 C, /5 30 sec), annealing (55 C, 1 min) and extension (68 C, 10 min) was performed. After the reaction, the template plasmid was digested by Dpn I, and each of obtained pPIC9-HSA(D63N), pPIC9-HSA(A320T) and pPIC9-HSA(D494N) were transfected into XL-10-Gold ultracompetent cells to perform transformation. The 20 transformants, which were transfected with the objective plasmid pPIC9-HSA(D63N), pPIC9-HSA(A320T) or pPIC9-HSA(D494N), were screened in ampicillin-added medium, and the plasmids were purified from the obtained transformants (QIAprep Spin Miniprep Kit, manufactured by QIAGEN). Confirmation of the 25 mutations were performed by ABI Prism 310 Genetic Analyzer (Applied Biosystems) using D63N sequence primer of SEQ ID NO:
11 (5'-GAAAATTTCGACGCCTTGGTGTTGATTGCC-3') for pPIC9-HSA(D63N), A320T sequence primer of SEQ ID NO: 12 (5'-GGCGGACCTTGCCGACTATATCTGTGA-3') for pPIC9-HSA(A320T), and 30 D494N sequence primer of SEQ ID NO: 13 (5'-GGTCTCAAGAAACCTAGGAAAAGTGGG-3') for pPIC9-HSA(D494N). Moreover, in order to prepare human serum albumin which was bonded by sugar chains at all three sites of Asn63, Asn318 and Asn494, mutation of N-linked sugar chain consensus sequence was 35 performed in the same way using above-prepared pPIC9-HSA(D63N) as a template, and A320T sense primer of SEQ ID NO: 7 and A320T antisense primer of SEQ ID NO: 8 as synthetic primers (QuikChange XL Site-Directed Mutagenesis Kit, Stratagene).
Using thus prepared pPIC9-HSA(D63N/A320T) as a template, and D494N sense primer of SEQ ID NO: 9 and D494N antisense primer of SEQ ID NO: 10 as synthetic primers, mutation was performed (QuikChange XL Site-Directed Mutagenesis Kit, Stratagene) in the same way to prepare pPIC9-HSA(D63N/A320T/D494N).
(2) expression of glycosylated human serum albumin .zo Each of pPIC9-HSA(D63N), pPIC9-HSA(A320T), pPIC9-HSA(D494N) and pPIC9-HSA(D63N/A320T/D494N) was digested with restriction enzyme Sal I, purified by phenol extraction and ethanol precipitation, and subsequently transformed into HIS4 gene locus of Pichia yeast (GS115 strain) by homologous recombination using an electroporation apparatus (Gene Pulser II Electroporation System, manufactured by BIO-RAD). The obtained transformants were cultured in BMMY liquid medium, and stocked in glycerol after confirmation of expression of albumin.
(3) purification of glycosylated albumin The transformed Pichia yeast was cultured in BMGY liquid medium for 48 hr, and subsequently in BMMY medium for 96 hr as adding 1% methanol every 12 hr. The yeast was separated by centrifugation (6,000g x 10 min.), after which the culture supernatant was dialyzed against 200 mM acetate buffer. Then, albumin was bonded to Blue Sepharose CL-6B column (manufactured by Amersham Biosciences), and eluted by concentration gradient of 0 to 3 M NaCl. Subsequently, this eluate was dialyzed against 0.65 M ammonium sulfate/100 mM
sodium phosphate buffer (pH 7.0), and passed through HiTrap Phenyl HP column (manufactured by Amersham Biosciences), and the nonadsorbed fraction was recovered. After that, defatting by activated carbon was performed.
Comparative Example 1 production of nonglycosylated (wild-type) human serum albumin Manipulated in the same manner as in Example, except that mutation of N-linked sugar chain consensus sequence was not performed, nonglycosylated human serum albumin was expressed in Pichia yeast, and human serum albumin (HSA) was obtained.
(4) Experimental Example 1 Glycosylated albumin, which was prepared in the same way as in Example, was labeled with radioactive indium isotope (mIn) to prepare "In-glycosylated albumin (D63N, A320T, D494N
and D63N/A320T/D494N).
glycosylated albumin was administered intravenously through the tail into a mouse (dose; 1 mg/kg), blood and liver were collected at fixed intervals after the administration, and albumin concentration and liver transfer were measured by radiation dose measuring equipment. As a control, human serum albumin obtained in /5 Comparative Example 1 was labeled with mIn ("In-human serum albumin), which was administered into a mouse, and measurement was carried out in the same way. Proportion of glycosylated albumin concentration in plasma and liver based on elapsed time after the administration and dose, namely transferability to liver (Hepatic accumulation (% of dose)), is shown in Fig.
1.
The result from Fig. 1 illustrates that glycosylated albumin, particularly D494N and D63N/A320T/D494N, rapidly vanishes from blood and is actively introduced to liver. Also, from the remarkable difference of in vivo kinetics among D63N, A320T and D494N, it is suggested that liver transferability of glycosylated albumin be largely dependent on the binding site of a sugar chain, in addition to the sugar density of the molecular surface so far been proposed.
(5) Experimental Example 2 Charge states of the "In-glycosylated albumin from Example (D63N, A320T, D494N and D63N/A320T/D494N) and the human serum albumin from Comparative Example 1 were evaluated using laser electrophoresis-zeta potential analyzer (LEZA-500T). As shown in Table 1, significant difference of the charge was not found in all of the variants prepared in this study compared to nonglycosylated albumin (HSA). From this, it can be said that albumin which has been subjected to glycosylation modification by eukaryotic cell has little difference of the charge of protein relative to the one which has not been subjected to, and sufficiently maintains its intrinsic properties of the protein.
On the other hand, when the liver transfer (Hepatic accumulation (% of dose)) at 60 min was read from Fig. 1 io (Table 1), that of glycosylated albumin was 6 - 65 times higher than that of nonglycosylated albumin (HSA). This proved that liver transferability was enhanced while maintaining the properties of albumin protein.
/5 Table 1 various albumin derived from Comparative HSA -0.311 0.97 genetic Example 1 engineering Example D63N -0.304 10.77 A320T -0.300 5.97 D494N -0.298 49.31 D63N/A320T/D494N -0.302 65.51 chemical Comparative BSA -0.353 1 modification Example 2 Suc28-BSA -0.588 23 (non-patent Suc28-BSA -0.946 63 reference Suc40-BSA -1.277 57 3) Suc46-BSA -1.672 49 Suc54-BSA -1.912 47 Comparative Example 2 Referring to figures presented in non-patent reference 3, chemically modified albumin was compared (Fig. 2, Table 1).
Table 1 presents values read from Fig. 2. The chemical 20 modification is a result of succinic acid (Suc) modification (an imide bond with E-amino group of a Lys residue in bovine serum albumin (BSA)), and "Sucn-BSA" represents a BSA to which n succinic acids are bonded.
From experiments using chemically modified albumin (BSA), it has been shown that negative-charge density on molecular surface of modified form is important for liver transfer, and thus it has been recognized until now that the greater the negative-charge becomes (the more the modification rate increases), the greater the extent of recognition by the liver becomes (see non-patent reference 3). However, the result shows that albumin modified with as much as 20 succinic acid molecules can acquire liver transferability.
On the other hand, while the charge of the non-modified BSA was about -0.35, the BSAs modified by succinic acids were not less than -0.5. Therefore, it is presumable that chemically modified albumin is heavily affected in its protein /5 structure and function by the charge change on its molecular surface.
The glycosylated albumin of the present invention can be used as a drug carrier for DDS targeting liver nonparenchymal cells, particularly kupffer's cells. Also, utilizing gene recombinant proteins and host's glycosylation modification mechanism, uniform proteins can be produced compared to in chemical modification methods, and modification operations can be omitted. Furthermore, there is no risk of contamination of virus and the like, so it can be safely administered to living organisms for medical purposes.
While the present invention has been described with emphasis on preferred embodiments, it is obvious to those skilled in the art that the preferred embodiments can be modified. The present invention intends that the present invention can be embodied by methods other than those described in detail in the present specification. Accordingly, the present invention encompasses all modifications encompassed in the scope of the appended "CLAIMS."

SEQUENCE LISTING IN ELECTRONIC FORM
In accordance with Section 111(1) of the Patent Rules, this description contains a sequence listing in electronic form in ASCII
text format (file: 28931-45 Seq 17-06-14 v2.txt).
A copy of the sequence listing in electronic form is available from the Canadian Intellectual Property Office.
The sequences in the sequence listing in electronic form are reproduced in the following table.
SEQUENCE TABLE
<110> Nipro Corporation <120> Sugar Chain-Containing Albumin, Production Method Thereof and Use Thereof <130> A7649 <140> CA 2611540 <141> 2007-11-09 <160> 13 <170> PatentIn version 3.3 <210> 1 <211> 1827 <212> DNA
<213> Artificial sequence <220>
<223> DNA encoding mutant ESA having glycosylation site(s) <220>
<221> CDS
<222> (1)..(1827) <220>
<221> sig_peptide <222> (1)..(54) <220>
<221> mat peptide <222> (73)..(1827) <400> 1 atg aag tgg gta acc ttt att tcc ctt ctt ttt ctc ttt agc tcg gct 48 Met Lys Trp Val Thr Phe Ile Ser Leu Leu Phe Leu Phe Ser Ser Ala =
tat tcc agg ggt gtg ttt cgt cga gat gca cac aag agt gag gtt got 96 Tyr Ser Arg Gly Val Phe Arg Arg Asp Ala His Lys Ser Glu Val Ala cat cgg ttt aaa gat ttg gga gaa gaa aat ttc aaa gcc ttg gtg ttg 144 His Arg Phe Lys Asp Leu Gly Glu Glu Asn Phe Lys Ala Leu Val Leu att gcc ttt got cag tat ctt cag cag tgt cca ttt gaa gat cat gta 192 Ile Ala Phe Ala Gln Tyr Leu Gln Gln Cys Pro Phe Glu Asp His Val aaa tta gtg aat gaa gta act gaa ttt gca aaa aca tgt gtt got gat 240 Lys Leu Val Asn Glu Val Thr Glu Phe Ala Lys Thr Cys Val Ala Asp gag tca got gaa aat tgt rac aaa tca ctt cat acc ctt ttt gga gac 288 Glu Ser Ala Glu Asn Cys Xaa Lys Ser Leu His Thr Leu Phe Gly Asp aaa tta tgc aca gtt gca act ctt cgt gaa acc tat ggt gaa atg gct 336 Lys Leu Cys Thr Val Ala Thr Leu Arg Glu Thr Tyr 61y Glu Met Ala gac tgc tgt gca aaa caa gaa cot gag aga aat gaa tgc ttc ttg caa 384 Asp Cys Cys Ala Lys Gln Glu Pro Glu Arg Asn Glu Cys Phe Leu Gln cac aaa gat gac aac cca aac ctc coo cga ttg gtg aga cca gag gtt 432 His Lys Asp Asp Asn Pro Asn Leu Pro Arg Leu Val Arg Pro Glu Val gat gtg atg tgC act got ttt cat gac aat gaa gag aca ttt ttg aaa 480 Asp Val Met Cys Thr Ala Phe His Asp Asn Glu Glu Thr Phe Leu Lys aaa tac tta tat gaa att gcc aga aga cat cot tac ttt tat gcc cog 528 Lys Tyr Leu Tyr Glu Ile Ala Arg Arg His Pro Tyr Phe Tyr Ala Pro gaa ctc ctt ttc ttt got aaa agg tat aaa got got ttt aca gaa tgt 576 Glu Leu Leu Phe Phe Ala Lys Arg Tyr Lys Ala Ala Phe Thr Glu Cys =
tgc caa got got gat aaa got gcc tgc ctg ttg cca aag ctc gat gaa 624 Cys Gln Ala Ala Asp Lys Ala Ala Cys Leu Leu Pro Lys Leu Asp Glu ctt cgg gat gaa ggg aag got tog tot gcc aaa cag aga ctc aag tgt 672 Lou Arg Asp Glu Gly Lys Ala Ser Ser Ala Lys Gln Arg Leu Lys Cys gcc agt ctc caa aaa ttt gga gaa aga got ttc aaa gca tgg gca gta 720 Ala Ser Leu Gln Lys Phe Gly Glu Arg Ala Phe Lys Ala Trp Ala Val . 205 210 215 got cgc ctg agc cag aga ttt ccc aaa gct gag ttt gca gaa gtt tcc 768 Ala Arg Leu Ser Gin Arg Phe Pro Lys Ala Glu Phe Ala Glu Val Ser aag tta gtg aca gat ctt acc aaa gtc cac acg gaa tgc tgc cat gga 816 Lys Leu Val Thr Asp Leu Thr Lys Val His Thr Glu Cys Cys His Gly gat ctg ctt gaa tgt got gat gac agg gcg gac ctt gcc aag tat atc 864 Asp Leu Leu Glu Cys Ala Asp Asp Arg Ala Asp Leu Ala Lys Tyr Ile tgt gaa aat caa gat tog atc too agt aaa ctg aag gaa tgc tgt gaa 912 Cys Glu Asn Gin Asp Ser Ile Ser Ser Lys Leu Lys Glu Cys Cys Glu aaa cct ctg ttg gaa aaa too cac tgc att goo gaa gtg gaa aat gat 960 Lys Pro Leu Leu Glu Lys Ser His Cys Ile Ala Glu Val Glu Asn Asp gag atg cct got gac ttg cct tca tta got got gat ttt gtt gaa agt 1008 Glu Met Pro Ala Asp Leu Pro Ser Leu Ala Ala Asp Phe Val Glu Ser aag gat gtt tgc aaa aac tat rot gag gca aag gat gtc ttc ctg g9c 1056 Lys Asp Val Cys Lys Asn Tyr Xaa Glu Ala Lys Asp Val Phe Leu Gly atg ttt ttg tat gaa tat gca aga agg cat cct gat tac tot gtc gtg 1104 Met Phe Leu Tyr Glu Tyr Ala Arg Arg His Pro Asp Tyr Ser Val Val ctg ctg ctg aga ctt goo aag aca tat gaa acc act cta gag aag tgc 1152 Leu Leu Leu Arg Leu Ala Lys Thr Tyr Glu Thr Thr Leu Glu Lys Cys =
tgt goo got gca gat cct cat gaa tgc tat gcc aaa gtg ttc gat gaa 1200 Cys Ala Ala Ala Asp Pro His Glu Cys Tyr Ala Lys Val Phe Asp Glu ttt aaa cct ctt gtg gaa gag cct cag aat tta atc aaa caa aat tgt 1248 Phe Lys Pro Leu Val Glu Glu Pro Gin Asn Leu Ile Lys Gin Asn Cys gag ctt ttt gag cag ctt gga gag tac aaa ttc cag aat gcg cta tta 1296 Glu Leu Phe Glu Gin Leu Gly Glu Tyr Lys Phe Gin Asn Ala Leu Leu 395 . 400 405 gtt cgt tac acc aag aaa gta coo caa gtg tca act cca act ctt gta 1344 Val Arg Tyr Thr Lys Lys Val Pro Gin Val Ser Thr Pro Thr Leu Val gag gtc tca aga aac cta gga aaa gtg ggc ago aaa tgt tgt aaa cat 1392 Glu Val Ser Arg Asn Leu Gly Lys Val Gly Ser Lys Cys Cys Lys His cot gaa gca aaa aga atg ccc tgt gca gaa gac tat cta tcc gtg gtc 1440 Pro Glu Ala Lys Arg Met Pro Cys Ala Glu Asp Tyr Leu Ser Val Val ctg aac cag tta tgt gtg ttg cat gag aaa acg cca gta agt gac aga 1488 Leu Asn Gln Leta Cys Val Leu His Glu Lys Thr Pro Val Ser Asp Arg gtc acc aaa tgc tgc aca gaa tcc ttg gtg aac agg cga cca tgc ttt 1536 Val Thr Lys Cys Cys Thr Glu Ser Leu Val Asn Arg Arg Pro Cys Phe tca got ctg gaa gtc rat gaa aca tac gtt coo aaa gag ttt aat got 1584 Ser Ala Leu Glu Val Xaa Glu Thr Tyr Val Pro Lys Glu Phe Asn Ala gaa aca ttc acc ttc cat gca gat ata tgc aca ctt tot gag aag gag 1632 Glu Thr Phe Thr Phe His Ala Asp Ile Cys Thr Leu Ser Glu Lys Glu aga caa atc aag aaa caa act gca ctt gtt gag ctc gtg aaa cac aag 1680 Arg Gln Ile Lys Lys Gln Thr Ala Leu Val Glu Leu Val Lys His Lys coo aag gca aca aaa gag caa ctg aaa got gtt atg gat gat ttc gca 1728 Pro Lys Ala Thr Lys Glu Gln Leu Lys Ala Val Met Asp Asp Phe Ala got ttt gta gag aag tgc tgc aag got gac gat aag gag acc tgc ttt 1776 Ala Phe Val Glu Lys Cys Cys Lys Ala Asp Asp Lys Glu Thr Cys Phe gcc gag gag ggt aaa aaa ctt gtt got gca agt caa got gcc tta ggc 1824 Ala Glu Glu Gly Lys Lys Leu Val Ala Ala Ser Gln Ala Ala Leu Gly tta 1827 Leu =

<210> 2 <211> 609 <212> PRT
<213> Artificial sequence <220>
<221> misc_feature <222> (63)..(63) <223> The 'Xaa' at location 63 stands for Asp, or Asn.
<220>
<221> misc_feature <222> (320)..(320) <223> The 'Xaa' at location 320 stands for Ala, or Thr. =
=

<220>
<221> misc feature <222> (494)..(494) <223> The 'Xaa' at location 494 stands for Asp, or Asn.
<220>
<223> Synthetic Construct <400> 2 Met Lys Trp Val Thr Phe Ile Ser Leu Leu Phe Leu Phe Ser Ser Ala Tyr Ser Arg Gly Val Phe Arg Arg Asp Ala His Lys Ser Glu Val Ala His Arg Phe Lys Asp Leu Gly Glu Glu Asn Phe Lys Ala Leu Val Leu Ile Ala Phe Ala Gin Tyr Leu Gin Gin Cys Pro Phe Glu Asp His Val Lys Leu Val Asn Glu Val Thr Glu Phe Ala Lys Thr Cys Val Ala Asp Glu Ser Ala Glu Asn Cys Xaa Lys Ser Leu His Thr Leu Phe Gly Asp Lys Leu Cys Thr Val Ala Thr Leu Arg Glu Thr Tyr Gly Glu Met Ala Asp Cys Cys Ala Lys Gin Glu Pro Glu Arg Asn Glu Cys Phe Leu Gin His Lys Asp Asp Asn Pro Asn Leu Pro Arg Leu Val Arg Pro Glu Val Asp Val Met Cys Thr Ala Phe His Asp Asn Glu Glu Thr Phe Leu Lys Lys Tyr Leu Tyr Glu Ile Ala Arg Arg His Pro Tyr Phe Tyr Ala Pro Glu Leu Leu Phe Phe Ala Lys Arg Tyr Lys Ala Ala Phe Thr Glu Cys Cys Gin Ala Ala Asp Lys Ala Ala Cys Lou Leu Pro Lys Leu Asp Glu Leu Arg Asp Glu Gly Lys Ala Ser Ser Ala Lys Gin Arg Leu Lys Cys Ala Ser Leu Gin Lys Phe Gly Glu Arg Ala Phe Lys Ala Trp Ala Val =
Ala Arg Leu Ser Gin Arg Phe Pro Lys Ala Glu Phe Ala Glu Val Ser Lys Leu Val Thr Asp Leu Thr Lys Val His Thr Glu Cys Cys His Gly Asp Leu Leu Glu Cys Ala Asp Asp Arg Ala Asp Leu Ala Lys Tyr Ile Cys Glu Asn Gin Asp Ser Ile Ser Ser Lys Leu Lys Glu Cys Cys Glu Lys Pro Leu Leu Glu Lys Ser His Cys Ile Ala Glu Val Glu Asn Asp Glu Met Pro Ala Asp Leu Pro Ser Leu Ala Ala Asp Phe Val Glu Ser Lys Asp Val Cys Lys Asn Tyr Xaa Glu Ala Lys Asp Val Phe Lou Gly Met Phe Lou Tyr Glu Tyr Ala Arg Arg His Pro Asp Tyr Ser Val Val Leu Leu Leu Arg Leu Ala Lys Thr Tyr Glu Thr Thr Leu Glu Lys Cys Cys Ala Ala Ala Asp Pro His Glu Cys Tyr Ala Lys Val Phe Asp Glu 365 370 375 .
Phe Lys Pro Leu Val Glu Glu Pro Gln Asn Leu Ile Lys Gln Asn Cys Glu Leu Phe Glu Gln Leu Gly Glu Tyr Lys Phe Gln Asn Ala Leu Leu Val Arg Tyr Thr Lys Lys Val Pro Gln Val Ser Thr Pro Thr Leu Val Glu Val Ser Arg Asn Leu Gly Lys Val Gly Ser Lys Cys Cys Lys His Pro Glu Ala Lys Arg Met Pro Cys Ala Glu Asp Tyr Leu Ser Val Val Leu Asn Gln Leu Cys Val Leu His Glu Lys Thr Pro Val Ser Asp 4g Val Thr Lys Cys Cys Thr Glu Ser Leu Val Asn Arg Arg Pro Cys Phe Ser Ala Leu Glu Val Xaa Glu Thr Tyr Val Pro Lys Glu Phe Asn Ala Glu Thr Phe Thr Phe His Ala Asp Ile Cys Thr Leu Ser Glu Lys Glu Arg Gln Ile Lys Lys Gln Thr Ala Leu Val Glu Leu Val Lys His Lys Pro Lys Ala Thr Lys Glu Gln Leu Lys Ala Val Met Asp Asp Phe Ala Ala Phe Val Glu Lys Cys Cys Lys Ala Asp Asp Lys Glu Thr Cys Phe Ala Glu Glu Gly Lys Lys Leu Val Ala Ala Ser Gln Ala Ala Leu Gly Leu <210> 3 <211> 1827 <212> DNA
<213> Homo sapiens =
<220>
<221> CDS
<222> (1)..(1827) <220>
<221> sig_peptide <222> (1)..(54) <220>
<221> mat peptide <222> (73)..(1827) <400> 3 atg aag tgg gta acc ttt att tcc ctt ctt ttt ctc ttt agc tcg gct 48 Met Lys Trp Val Thr Phe Ile Ser Leu Leu Phe Leu Phe Ser Ser Ala tat tcc agg ggt gtg ttt cgt cga gat gca cac aag agt gag gtt gct 96 Tyr Ser Arg Gly Val Phe Arg Arg Asp Ala His Lys Ser Glu Val Ala cat cgg ttt aaa gat ttg gga gaa gaa aat ttc aaa gcc ttg gtg ttg 144 His Arg Phe Lys Asp Leu Gly Glu Glu Asn Phe Lys Ala Leu Val Leu att gcc ttt gct cag tat ctt cag cag tgt cca ttt gaa gat cat gta 192 Ile Ala Phe Ala Gin Tyr Leu Gin Gin Cys Pro Phe Glu Asp His Val aaa tta gtg aat gaa gta act gaa ttt gca aaa aca tgt gtt gct gat 240 Lys Leu Vsi Asn Glu Val Thr Glu Phe Ala Lys Thr Cys Val Ala Asp gag tca gct gaa aat tgt gac aaa tca ctt cat acc ctt ttt gga gac 288 Glu Ser Ala Glu Asn Cys Asp Lys Ser Leu His Thr Leu Phe Gly Asp aaa tta tgc aca gtt gca act ctt cgt gaa acc tat ggt gaa atg gct 336 Lys Leu Cys Thr Val Ala Thr Leu Arg Glu Thr Tyr Gly Glu Met Ala gac tgc tgt gca aaa caa gaa cct gag aga aat gaa tgc ttc ttg caa 384 Asp Cys Cys Ala Lys Gin Glu Pro Glu Arg Asn Glu Cys Phe Leu Gin cac aaa gat gac aac cca aac ctc ccc cga ttg gtg aga cca gag gtt 432 His Lys Asp Asp Asn Pro Asn Leu Pro Arg Leu Val Arg Pro Glu Val gat gtg atg tgc act gct ttt cat gac aat gaa gag aca ttt ttg aaa 480 Asp Val Met Cys Thr Ala Phe His Asp Asn Glu Glu Thr Phe Lou Lys aaa tac tta tat gaa att gcc aga aga cat cct tac ttt tat gcc cog 528 Lys Tyr Leu Tyr Glu Ile Ala Arg Arg His Pro Tyr Phe Tyr Ala Pro gaa ctc ctt ttc ttt gct aaa agg tat aaa gct gct ttt aca gaa tgt 576 Glu Leu Leu Phe Phe Ala Lys Arg Tyr Lys Ala Ala Phe Thr Glu Cys tgc caa gct gct gat aaa gct gcc tgc ctg ttg cca aag ctc gat gaa 624 Cys Gin Ala Ala Asp Lys Ala Ala Cys Leu Leu Pro Lys Leu Asp Glu ctt cgg gat gaa ggg aag gct tog tot gcc aaa cag aga ctc aag tgt 672 Leu Arg Asp Glu Gly Lys Ala Ser Ser Ala Lys Gin Arg Leu Lys Cys gcc agt ctc caa aaa ttt gga gaa aga gct ttc aaa gca tgg gca gta 720 Ala Ser Leu Gin Lys Phe Gly Glu Arg Ala Phe Lys Ala Trp Ala Val =

28931-45 =
gct cgc ctg agc cag aga ttt ccc aaa gct gag ttt gca gaa gtt tcc 768 Ala Arg Leu Ser Gin Arg Phe Pro Lys Ala Glu Phe Ala Glu Val Ser aag tta gtg aca gat ctt acc aaa gtc cac acg gaa tgc tgc cat gga 816 Lys Leu Val Thr Asp Leu Thr Lys Val His Thr Glu Cys Cys His Gly gat ctg ctt gaa tgt gct gat gac agg gcg gac ctt gcc aag tat atc 864 Asp Leu Leu Glu Cys Ala Asp Asp Arg Ala Asp Leu Ala Lys Tyr Ile tgt gaa aat caa gat tcg atc tcc agt aaa ctg aag gaa tgc tgt gaa 912 Cys Glu Asn Gin Asp Ser Ile Ser Ser Lys Leu Lys Glu Cys Cys Glu aaa cct ctg ttg gaa aaa tcc cac tgc att gcc gaa gtg gaa aat gat 960 Lys Pro Leu Leu Glu Lys Ser His Cys Ile Ala Glu Val Glu Asn Asp gag atg cct gct gac ttg cct tca tta gct gct gat ttt gtt gaa agt 1008 Glu Met Pro Ala Asp Leu Pro Ser Leu Ala Ala Asp Phe Val Glu Ser aag gat gtt tgc aaa aac tat gct gag gca aag gat gtc ttc ctg ggc 1056 Lys Asp Val Cys Lys Asn Tyr Ala Glu Ala Lys Asp Val Phe Leu Gly atg ttt ttg tat gaa tat gca aga agg cat cct gat tac tct gtc gtg 1104 .
Met Phe Leu Tyr Glu Tyr Ala Arg Arg His Pro Asp Tyr Ser Val Val ctg ctg ctg aga ctt gcc aag aca tat gaa acc act cta gag aag tgc 1152 Leu Leu Leu Arg Leu Ala Lys Thr Tyr Glu Thr Thr Leu Glu Lys Cys tgt gcc gct gca gat cct cat gaa tgc tat gcc aaa gtg ttc gat gaa 1200 Cys Ala Ala Ala Asp Pro His Glu Cys Tyr Ala Lys Val Phe Asp Glu =
ttt aaa cct ctt gtg gaa gag cct cag aat tta atc aaa caa aat tgt 1248 Phe Lys Pro Leu Val Glu Glu Pro Gin Asn Leu Ile Lys Gin Asn Cys gag ctt ttt gag cag ctt gga gag tac aaa ttc cag aat gcg cta tta 1296 Glu Leu Phe Glu Gin Leu Gly Glu Tyr Lys Phe Gin Asn Ala Leu Leu gtt cgt tac acc aag aaa gta ccc caa gtg tca act cca act ctt gta 1344 Val Arg Tyr Thr Lys Lys Val Pro Gin Val Ser Thr Pro Thr Leu Val 410 415 420 =
gag gtc tca aga aac cta gga aaa gtg ggc agc aaa tgt tgt aaa cat 1392 Glu Val Ser Arg Asn Leu Gly Lys Val Gly Ser Lys Cys Cys Lys His cot gaa gca aaa aga atg ccc tgt gca gaa gac tat cta tcc gtg gtc 1440 Pro Glu Ala Lys Arg Met Pro Cys Ala Glu Asp Tyr Leu Ser Val Val ctg aac cag tta tgt gtg ttg cat gag aaa acg cca gta agt gac aga 1488 Leu Asn Gln Leu Cys Val Leu His Glu Lys Thr Pro Val Ser Asp Arg gtc acc aaa tgc tgc aca gaa tcc ttg gtg aac agg cga cca tgc ttt 1536 Val Thr Lys Cys Cys Thr Glu Ser Leu Val Asn Arg Arg Pro Cys Phe tca got ctg gaa gtc gat gaa aca tac gtt ccc aaa gag ttt aat got 1584 Ser Ala Leu Glu Val Asp Glu Thr Tyr Val Pro Lys Glu Phe Asn Ala gaa aca ttc acc ttc cat gca gat ata tgc aca ctt tot gag aag gag 1632 Glu Thr Phe Thr Phe His Ala Asp Ile Cys Thr Leu Ser Glu Lys Glu aga caa atc aag aaa caa act gca ctt gtt gag ctc gtg aaa cac aag 1680 Arg Gln Ile Lys Lys Gln Thr Ala Leu Val Glu Leu Val Lys His Lys . 525 530 535 ccc aag gca aca aaa gag caa ctg aaa get gtt atg gat gat ttc gca 1728 Pro Lys Ala Thr Lys Glu Gln Leu Lys Ala Val Met Asp Asp Phe Ala got ttt gta gag aag tgc tgc aag got gac gat aag gag acc tgc ttt 1776 Ala Phe Val Glu Lys Cys Cys Lys Ala Asp Asp Lys Glu Thr Cys Phe gcc gag gag ggt aaa aaa ctt gtt got gca agt caa got gcc tta ggc 1824 Ala Glu Glu Gly Lys Lys Leu Val Ala Ala Ser Gln Ala Ala Leu Gly tta 1827 Leu <210> 4 <211> 609 <212> PRT
<213> Homo sapiens <400> 4 Met Lys Trp Val Thr Phe Ile Ser Leu Leu Phe Leu Phe Ser Ser Ala Tyr Ser Arg Gly Val Phe Arg Arg Asp Ala His Lys Ser Glu Val Ala His Arg Phe Lys Asp Leu Gly Glu Glu Asn Phe Lys Ala Leu Val Leu Ile Ala Phe Ala Gln Tyr Leu Gln Gln Cys Pro Phe Glu Asp His Val Lys Leu Val Asn Glu Val Thr Glu Phe Ala Lys Thr Cys Val Ala Asp Glu Ser Ala Glu Asn Cys Asp Lys Ser Leu His Thr Leu Phe Gly Asp 60. 65 70 Lys Lou Cys Thr Val Ala Thr Leu Arg Glu Thr Tyr Gly Glu Met Ala Asp Cys Cys Ala Lys Gin Glu Pro Glu Arg Asn Glu Cys Phe Leu Gln His Lys Asp Asp Asn Pro Asn Leu Pro Arg Leu Val Arg Pro Glu Val Asp Val Met Cys Thr Ala Phe His Asp Asn Glu Glu Thr Phe Leu Lys Lys Tyr Leu Tyr Glu Ile Ala Arg Arg His Pro Tyr Phe Tyr Ala Pro Glu Leu Leu Phe Phe Ala Lys Arg Tyr Lys Ala Ala Phe Thr Glu Cys Cys Gin Ala Ala Asp Lys Ala Ala Cys Leu Leu Pro Lys Leu Asp Glu Leu Arg Asp Glu Gly Lys Ala Ser Ser Ala Lys Gin Arg Leu Lys Cys Ala Ser Lou Gin Lys Phe Gly Glu Arg Ala Phe Lys Ala Trp Ala Val Ala Arg Leu Ser Gin Arg Phe Pro Lys Ala Glu Phe Ala Glu Val Ser Lys Leu Val Thr Asp Leu Thr Lys Val His Thr Glu Cys Cys His Gly 235 . 240 245 Asp Leu Lou Glu Cys Ala Asp Asp Arg Ala Asp Leu Ala Lys Tyr Ile Cys Glu Asn Gin Asp Ser Ile Ser Ser Lys Leu Lys Glu Cys Cys Glu Lys Pro Leu Leu Glu Lys Ser His Cys Ile Ala Glu Val Glu Asn Asp Glu Met Pro Ala Asp Leu Pro Ser Lou Ala Ala Asp Phe Val Glu Ser 300 305 310 =
Lys Asp Val Cys Lys Asn Tyr Ala Glu Ala Lys Asp Val Phe Leu Gly Met Phe Leu Tyr Glu Tyr Ala Arg Arg His Pro Asp Tyr Ser Val Val Leu Leu Lou Arg Leu Ala Lys Thr Tyr Glu Thr Thr Leu Glu Lys Cys Cys Ala Ala Ala Asp Pro His Glu Cys Tyr Ala Lys Val Phe Asp Glu Phe Lys Pro Leu Val Glu Glu Pro Gin Asn Leu Ile Lys Gin Asn Cys Glu Leu Phe Glu Gin Lou Gly Glu Tyr Lys Phe Gin Asn Ala Leu Lou Val Arg Tyr Thr Lys Lys Val Pro Gin Val Ser Thr Pro Thr Leu Val Glu Val Ser Arg Asn Leu Gly Lys Val Gly Ser Lys Cys Cys Lys His Pro Glu Ala Lys Arg Met Pro Cys Ala Glu Asp Tyr Leu Ser Val Val Leu Asn Gin Leu Cys Val Leu His Glu Lys Thr Pro Val Ser Asp Arg Val Thr Lys Cys Cys Thr Glu Ser Leu Val Asn Arg Arg Pro Cys Phe Ser Ala Leu Glu Val Asp Glu Thr Tyr Val Pro Lys Glu Phe Asn Ala Glu Thr Phe Thr Phe His Ala Asp Ile Cys Thr Leu Ser Glu Lys Glu Arg Gln Ile Lys Lys Gln Thr Ala Leu Val Glu Leu Val Lys His Lys Pro Lys Ala Thr Lys Glu Gln Leu Lys Ala Val Met Asp Asp Phe Ala Ala Phe Val Glu Lys Cys Cys Lys Ala Asp Asp Lys Glu Thr Cys Phe Ala Glu Glu Gly Lys Lys Leu Val Ala Ala Ser Gln Ala Ala Leu Gly Leu =
<210> 5 <211> 37 <212> DNA
<213> Artificial sequence <220>
<223> Primer <400> 5 gagtcagctg aaaattgtaa caaatcactt cataccc 37 <210> 6 <211> 37 =
<212> DNA
<213> Artificial sequence <220>
<223> Primer <400> 6 gggtatgaag tgatttgtta caattttcag ctgactc 37 <210> 7 <211> 32 <212> DNA
<213> Artificial sequence <220>
<223> Primer <400> 7 ggatgtttgc aaaaactata ctgaggcaaa gg 32 <210> 8 <211> 32 <212> DNA
<213> Artificial sequence <220>
<223> Primer <400> 8 cctttgcctc agtatagttt ttgcaaacat cc 32 <210> 9 <211> 30 <212> DNA
<213> Artificial sequence =
<220>
<223> Primer <400> 9 gctctggaag tcaatgaaac atacgttccc 30 <210> 10 <211> 30 <212> DNA
<213> Artificial sequence <220>
<223> Primer <400> 10 gggaacgtat gtttcattga cttccagagc 30 <210> 11 <211> 30 <212> DNA
<213> Artificial sequence <220>
<223> Primer <400> 11 gaaaatttcg acgccttggt gttgattgcc 30 <210> 12 <211> 27 <212> DNA
<213> Artificial sequence <220>
<223> Primer <400> 12 ggcggacctt gccgactata tctgtga 27 <21o> 13 <211> 27 <212> DNA
<213> Artificial sequence <220>
<223> Primer <400> 13 ggtctcaaga,aacctaggaa aagtggg 27

Claims (7)

CLAIMS:
1. A glycosylated albumin protein comprising a mutant albumin and a sugar chain for use as a drug carrier to the liver, wherein the mutant albumin (i) has an amino acid sequence having not less than 90% identity to the amino acid sequence of wild-type mature human serum albumin (HSA) shown in amino acids 1-585 of SEQ ID
NO:4, (ii) contains one or more mutations selected from:
(a) substitution of Asp residue shown by amino acid number 63 in the amino acid sequence of SEQ ID No:4 with Asn residue;
(b) substitution of Ala residue shown by amino acid number 320 in the amino acid sequence of SEQ ID No:4 with Thr residue; and (c) substitution of Asp residue shown by amino acid number 494 in the amino acid sequence of SEQ ID No:4 with Asn residue;
to constitute partial amino acid sequence(s) that is (are) subject to a glycosylation modification by an eukaryotic cell, and wherein the sugar chain is selectively added to the partial amino acid sequence(s) by the eukaryotic cell containing a DNA encoding the mutant albumin.
2. The glycosylated albumin protein for use as a drug carrier to the liver of claim 1, wherein the sugar chain is a high-mannose type sugar chain.
3. The glycosylated albumin protein for use as a drug carrier to the liver of claim 1 or 2, wherein at least the 494th amino acid is Asn.
4. The glycosylated albumin protein for use as a drug carrier to the liver of any one of claims 1 to 3, wherein the eukaryotic cell is a yeast.
5. The glycosylated albumin protein for use as a drug carrier to the liver of claim 4, wherein the yeast belongs to the genus Pichia.
6. A pharmaceutical composition comprising a pharmaceutical compound to be delivered to the liver, and the glycosylated albumin protein as defined in any one of claims 1 to 6, wherein the pharmaceutical compound is an antioxidative substance or nitric oxide.
7. The pharmaceutical composition of claim 6, which is targeted to a kupffer's cell.
CA2611540A 2007-11-09 2007-11-09 Sugar chain-containing albumin as a drug carrier to the liver Expired - Fee Related CA2611540C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2611540A CA2611540C (en) 2007-11-09 2007-11-09 Sugar chain-containing albumin as a drug carrier to the liver

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA2611540A CA2611540C (en) 2007-11-09 2007-11-09 Sugar chain-containing albumin as a drug carrier to the liver

Publications (2)

Publication Number Publication Date
CA2611540A1 CA2611540A1 (en) 2009-05-09
CA2611540C true CA2611540C (en) 2017-05-30

Family

ID=40620882

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2611540A Expired - Fee Related CA2611540C (en) 2007-11-09 2007-11-09 Sugar chain-containing albumin as a drug carrier to the liver

Country Status (1)

Country Link
CA (1) CA2611540C (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG172789A1 (en) 2009-02-11 2011-08-29 Novozymes Biopharma Dk As Albumin variants and conjugates
BR112012009450A2 (en) 2009-10-30 2017-05-23 Novozymes Biopharma Dk As albumin variants
EP2556087A1 (en) 2010-04-09 2013-02-13 Novozymes Biopharma DK A/S Albumin derivatives and variants
EP2780364A2 (en) 2011-11-18 2014-09-24 Eleven Biotherapeutics, Inc. Proteins with improved half-life and other properties
ES2664328T3 (en) 2012-03-16 2018-04-19 Albumedix A/S Albumin variants
CA2890766A1 (en) 2012-11-08 2014-05-15 Novozymes Biopharma Dk A/S Albumin variants
CA2989966C (en) 2015-08-20 2024-04-30 Albumedix A/S Albumin variants and conjugates
HRP20210635T1 (en) * 2015-09-08 2021-08-20 Jcr Pharmaceuticals Co., Ltd. NEW MUTANT OF HUMAN SERUM ALBUMIN
CN112516288B (en) * 2020-12-22 2023-04-18 西藏阿那达生物医药科技有限责任公司 Application of N-glycosylation modified ganoderma lucidum immunomodulatory protein

Also Published As

Publication number Publication date
CA2611540A1 (en) 2009-05-09

Similar Documents

Publication Publication Date Title
CA2611540C (en) Sugar chain-containing albumin as a drug carrier to the liver
US7943570B2 (en) Sugar chain-containing albumin, production method thereof and use thereof
JP2662390B2 (en) Insiulin analog
JP4983148B2 (en) Glycan-containing albumin, method for producing the same, and use thereof
CN1119421C (en) Growth hormone and serum albumin recombinant fusion protein
EP2598525B1 (en) Frataxin mutants
EP2502939B1 (en) Nonnatural collagen-like protein and use thereof
EP3260139A2 (en) Long-acting insulin or insulin analogue complex
KR20040095217A (en) Albumin-Fused Anti-Angiogenesis Peptides
CN103641896B (en) The purposes of gelatin-like unit
CN112210572B (en) Preparation method of recombinant human antibody fusion protein
EP3838925A1 (en) Long-acting recombinant glp1-fc-cd47 protein, preparation method and use thereof
CN111040021B (en) Carrier protein for improving bioactive protein property
CA3254188A1 (en) Human insulin analogue, and fusion protein thereof and medical use thereof
EP2058331B1 (en) Sugar chain-containing albumin, production method and use thereof
KR20220083784A (en) Method for producing a fusion protein of serum albumin and growth hormone
US10968267B2 (en) Serum albumin-20K growth hormone fusion protein
KR20090040185A (en) Sugar chain-containing albumin, method for producing the same and use thereof
JP2010172277A (en) Method for producing albumin variant having high ligand affinity
CN120053605A (en) Central targeting system for treating type II diabetes based on fibroblast growth factor
CN101429240A (en) Albumin containing sugar chain, preparation method and uses thereof

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20191112